Phase 1 · NCT06982859
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
- ClinicalTrials.gov ID
- NCT06982859
- Indication
- Diabetes Mellitus, Insulin Sensitivity
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 95
- Status
- Active, not recruiting
- Interventions
- Drug: Retatrutide; Drug: Semaglutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – 70 Years
- Locations
- 1 site · Germany
- Study start
- 2 Jun 2025
- Primary completion
- 1 Jan 2027
- Study completion
- 1 Jan 2027
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 6 Oct 2026
Endpoints
Primary
Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo
Secondary
Change from Baseline in cDI for Comparison Between Retatrutide and Semaglutide; Change from Baseline in Hyperinsulinemic Euglycemic Clamp M-value; Change from Baseline in First Phase Incremental Insulin Secretion Rate (ISR); Change from Baseline in Second Phase Total ISR; Change from Baseline in Total ISR; Change from Baseline in Insulin Response to Arginine [Incremental Insulin Area Under the Curve (AUC) arginine, 0-10minutes]; Change from Baseline in Insulin Response to Arginine (Incremental Insulin AUC arginine, 0-30minutes); Change from Baseline in Beta-cell (β-cell) Glucose Sensitivity (GS); Change from Baseline in β-cell Glucose Sensitivity (GS) from Standardized Mixed-Meal Tolerance Test (sMMTT); Change from Baseline in ISR at Fixed Glucose Concentration (ISRg) from sMMTT; Change from Baseline Fasting Glucose During sMMTT (Total and Incremental AUC0-240min); Change from Baseline Postmeal Glucose During sMMTT (Total and Incremental AUC0-240min)
Registry monitoring
Latest Trial Changes
| Field | Change | Detected | Source |
|---|---|---|---|
| Primary completion date | 2026-12-01→2027-01-01 | 7 Oct 2026 | ClinicalTrials.gov |
| Study completion date | 2026-12-01→2027-01-01 | 7 Oct 2026 | ClinicalTrials.gov |